Elucidata

Recognized as the 'Most Innovative Biotech Company, 2024', by Fast Company! Even today Early R&D, Precision Diagnostics and Translational Biomarker teams spend about 80% of their time wrangling data. Elucidata's mission is to empower scientists in the life sciences field by reclaiming every valuable hour for their research endeavors. Elucidata’s data harmonization platform - Polly, helps research teams make multi-modal biomedical data Machine Learning ready. Each dataset on Polly is processed consistently using pipelines of your choice, is custom curated with granular annotations and undergoes robust QA/QC checks to ensure highest data quality standards. Polly transforms multi-modal and multi-source biomedical data (Omics, Assay, Real World Data, Clinical & EHR Data, and CRO data) into a Unified Data Model. With our 10X faster LLM-powered curation and human-in-the-loop model to achieve 99.99% accuracy, we are fast-tracking time to analysis. Today, Polly is facilitating use case like patient stratification, biomarker discovery, target ID & validation, data management, and development of clinical and commercial pipelines across Pfizer, Janssen Pharmaceuticals, NextGen Jane and IMBDx and over 35 premier biopharma companies and research labs. Head-quarted in San Francisco, we are a 120+ multi-disciplinary team of experts based across the US and India. In September 2022, we raised $16 million in our Series A round led by Eight Roads and F-Prime along with our existing investors Hyperplane and IvyCap. Write to us at info@elucidata.io for queries To talk to us, visit: For more information, visit: Visit Our Offices - San Francisco Head Quarters: 114 Sansome Street, Suite 250 San Francisco, CA 94104 Boston Office: 625 Massachusetts Avenue Cambridge, MA 02139 R&D Hubs, India - Delhi and Bangalore